Humira (Adalimumab) Drug Intelligence — PatSnap Eureka
Humira (Adalimumab) Drug Intelligence Report
Adalimumab is a fully human anti-TNF-α monoclonal antibody originated by AbbVie, first approved in December 2002. It spans 22 indications across inflammatory and autoimmune diseases.
Adalimumab (Humira) — Global Drug Profile Overview
Adalimumab (brand name Humira) is a fully human monoclonal antibody originated by AbbVie, Inc. and first approved on December 31, 2002. It holds approved global development status and is actively commercialized by AbbVie entities across the United States, Germany, and Japan.
Adalimumab targets TNF-α (tumor necrosis factor-alpha), a pleiotropic pro-inflammatory cytokine central to autoimmune pathology. By binding soluble and membrane-bound hTNFα with high affinity (Kd ≤ 10⁻⁸ M), it prevents TNF-α from engaging TNFR1 and TNFR2 receptors, attenuating downstream NF-kB signaling, adhesion molecule expression, and secondary cytokine release.
The database records 22 total indications for adalimumab, spanning rheumatology, dermatology, and gastroenterology. Explicitly retrieved indications include non-radiographic axial spondyloarthritis, pyoderma gangrenosum, and pustular psoriasis, reflecting label expansion into rare inflammatory conditions beyond its original 2002 approval scope.
Active commercial organizations are consolidated entirely within AbbVie entities: AbbVie, Inc. (U.S.), AbbVie Deutschland GmbH & Co. KG (Germany/Europe), and AbbVie GK (Japan). Deal history involves a bilateral partnership with Eisai/EA Pharma across Japan-specific licensing (2008) and co-promotion (2016) agreements.
TNF-α Inhibitor Competitors and Biosimilar Entrants
Ten competitors are retrieved on the same TNF-α inhibitor target axis, spanning four originator biologics and six biosimilars. The competitive cohort includes etanercept (approved 1998), certolizumab pegol (2008), golimumab (2009), and three adalimumab-specific biosimilars approved between 2016 and 2023.
TNF-α Inhibitor Drugs by First Approval Year
Originator biologics and biosimilars on the TNF-α axis ranked by first approval date, from etanercept (1998) through the golimumab biosimilar entries in 2025–2026.
↗ Click bars to exploreAdalimumab Patent Filings by Theme — Active vs Inactive
Distribution of 20 retrieved patents across six thematic clusters, highlighting that only 2 remain active — one in manufacturing and one in drug delivery.
↗ Click bars to exploreAdalimumab Indications Across Inflammatory Disease Areas
The PatSnap Eureka database records 22 total indications for adalimumab, reflecting substantial label expansion since its original 2002 approval. Explicitly retrieved indications include rheumatological and dermatological conditions consistent with TNF-α inhibitor activity across immune-mediated inflammatory diseases.
Non-Radiographic Axial Spondyloarthritis
Non-radiographic axial spondyloarthritis is among the explicitly retrieved indications for adalimumab in the PatSnap Eureka database. This indication falls within rheumatology and represents label expansion beyond adalimumab’s original 2002 approval scope. It is consistent with TNF-α inhibitor utility across the spondyloarthritis disease spectrum.
RheumatologyPyoderma Gangrenosum
Pyoderma gangrenosum is an explicitly retrieved indication in the adalimumab database record, representing label extension into rare inflammatory skin conditions. This dermatological indication illustrates adalimumab’s breadth of TNF-α inhibitor applicability across tissue types. The 22 total indications in the database signal that adalimumab has been extended substantially beyond its core approval scope.
DermatologyPustular Psoriasis
Pustular psoriasis is among the explicitly retrieved indications for adalimumab, representing a rare and severe subtype of psoriatic skin disease. This indication reflects the pattern of label expansion into specialized dermatological conditions driven by adalimumab’s mechanism of TNF-α neutralization. The AbbVie–Eisai co-promotion agreement in Japan specifically targeted gastrointestinal and inflammatory disease indications, underscoring the breadth of commercial strategy around the molecule.
DermatologyGastrointestinal Disease Indications
The 2016 co-promotion agreement between AbbVie and EA Pharma (Eisai subsidiary) specifically targeted gastrointestinal disease indications for Humira in Japan, highlighting a commercially significant disease cluster within adalimumab’s 22 total indications. This Japan-specific commercial focus aligns with Crohn’s disease and related inflammatory bowel conditions where TNF-α inhibitors are established therapies. The deal represents a deepening of the AbbVie–Eisai relationship first established through the 2008 licensing agreement for additional Japanese indications.
GastroenterologyOrganizations in the Adalimumab Commercial and IP Ecosystem
Active commercial infrastructure for adalimumab is entirely consolidated within AbbVie entities across the U.S., Germany, and Japan. AbbVie Inc. and AbbVie Biotechnology Ltd together hold the only two enforceable patents retrieved, while deal history is bilaterally confined to AbbVie/Abbott and Eisai in the Japanese market.
Top Patent Assignees by Filing Count — Adalimumab Ecosystem
↗ Click bars to exploreAbbVie, Inc.
AbbVie, Inc. is the originator of adalimumab (Humira), holding active commercial status globally since the drug’s first approval on December 31, 2002. AbbVie Inc. holds 4 patents in the retrieved dataset with 1 active — US9090867B2 covering fed-batch mammalian cell culture manufacturing. AbbVie entities (U.S., Germany, Japan via AbbVie GK) constitute all active commercial organizations in this dataset.
United StatesAbbVie Biotechnology Ltd
AbbVie Biotechnology Ltd holds 3 patents in the retrieved adalimumab dataset, including 1 active patent — EP2560727A1 — covering wearable automatic injection devices for subcutaneous delivery, directly relevant to Humira’s administration modality. The entity also holds the core antibody structure disclosure (AU2013257402A1, now inactive) and variable dosing regimen patents. It represents the IP vehicle for AbbVie’s formulation and device-related protection strategy.
United Kingdom / GlobalStrategic Outlook for Adalimumab and the TNF-α Inhibitor Class
Adalimumab faces structurally accelerating biosimilar pressure across the TNF-α inhibitor class while AbbVie’s enforceable IP perimeter has narrowed to two active patents. Strategic positioning now depends on device innovation, Japan market dynamics, and an open biomarker landscape.
AbbVie’s Active IP Perimeter Is Narrow and Device-Concentrated
Only two active patents are retrieved in this dataset: US9090867B2 (fed-batch manufacturing, AbbVie Inc.) and EP2560727A1 (wearable auto-injection devices, AbbVie Biotechnology Ltd). The core antibody composition-of-matter patent AU2013257402A1 is now inactive, consistent with the biosimilar entry window observed from 2016 onward. IP strategists should monitor EP2560727A1 for expiry timing and potential design-around activity by biosimilar entrants such as Amgen, Mochida, and Nippon Kayaku.
Japan Market Warrants Targeted Intelligence Given Biosimilar and Deal Concentration
Both recorded deals for adalimumab involve Eisai and are Japan-specific: a 2008 license agreement (Abbott/Eisai) for additional indications and a 2016 co-promotion agreement (AbbVie/EA Pharma) for gastrointestinal disease. Simultaneously, two Japanese companies — Mochida Pharmaceutical (approved 2021) and Nippon Kayaku (approved 2023) — have launched adalimumab biosimilars in Japan. With AbbVie GK remaining an active entity, the Japanese market represents a high-competitive-intensity geography where the AbbVie–Eisai relationship may require revisiting under current biosimilar market pressure.
Adalimumab vs Etanercept — TNF-α Inhibitor Originator Comparison
Click any row to explore further in PatSnap Eureka.
| Dimension | Adalimumab (Humira) | Etanercept |
|---|---|---|
| Drug Type | Monoclonal antibody (fully human) | Fc fusion protein |
| Primary Target | TNF-α (Tumor Necrosis Factor-alpha) | TNF-α (Tumor Necrosis Factor-alpha) |
| Mechanism of Action | TNF-α inhibitor; binds soluble and membrane-bound hTNFα with Kd ≤ 10⁻⁸ M, blocking TNFR1 and TNFR2 engagement | TNF-α inhibitor; decoy receptor fusion protein that competitively binds TNF-α |
| Global Status | Approved | Approved |
| First Approved | 2002-12-31 | 1998-11-02 |
| Key Indications | 22 total indications including non-radiographic axial spondyloarthritis, pyoderma gangrenosum, pustular psoriasis, gastrointestinal disease | TNF-α inhibitor class; specific indication count not reported in dataset |
| Originator | AbbVie, Inc. | Not specified in dataset |
| Active Organizations | AbbVie, Inc.; AbbVie Deutschland GmbH & Co. KG; AbbVie GK (Japan) | Not specified in dataset; biosimilar by Lupin Ltd approved 2019-03-26 |
Frequently Asked Questions — Humira (Adalimumab)
Humira (adalimumab) is a fully human anti-TNF-α monoclonal antibody originated by AbbVie, Inc. It works by binding soluble and membrane-bound human tumor necrosis factor-alpha (hTNFα) with high affinity (Kd ≤ 10⁻⁸ M), preventing TNF-α from engaging its receptors TNFR1 and TNFR2. This neutralization attenuates downstream inflammatory signaling including NF-kB activation, adhesion molecule expression, and secondary cytokine release (IL-1, IL-6).
The PatSnap Eureka database records 22 total indications for adalimumab. Explicitly retrieved indications include non-radiographic axial spondyloarthritis (rheumatology), pyoderma gangrenosum (dermatology), and pustular psoriasis (dermatology). The 2016 co-promotion agreement with EA Pharma (Eisai) targeted gastrointestinal disease indications in Japan, reflecting a pattern of label expansion across inflammatory and autoimmune diseases since original approval in December 2002.
Adalimumab was originated by AbbVie, Inc. and first approved on December 31, 2002. Active commercial organizations in the dataset are entirely consolidated within AbbVie entities: AbbVie, Inc. (U.S.), AbbVie Deutschland GmbH & Co. KG (Germany/Europe), and AbbVie GK (Japan). No non-AbbVie organization holds an active commercial role in this dataset.
Ten competitors are retrieved on the same TNF-α inhibitor target axis. Originator biologics include etanercept (first approved 1998), certolizumab pegol (2008), and golimumab (2009). Direct adalimumab biosimilars include adalimumab-ATTO from Amgen (approved 2016), a Mochida Pharmaceutical biosimilar (2021, Japan), and a Nippon Kayaku biosimilar (2023, Japan). Golimumab biosimilars from Alvotech (2025) and Bio-Thera (2026) represent the most recent entries.
Two deals are recorded in the dataset for adalimumab. First, a license agreement dated January 29, 2008 between Abbott (predecessor to AbbVie) and Eisai for additional adalimumab indications in Japan. Second, a co-promotion agreement dated June 1, 2016 between AbbVie and EA Pharma (an Eisai subsidiary) to co-promote Humira for gastrointestinal disease in Japan. Financial values are undisclosed for both deals.
Among 20 patents retrieved, only 2 carry active status. The active patents are US9090867B2 (AbbVie Inc.) covering fed-batch mammalian cell culture manufacturing, and EP2560727A1 (AbbVie Biotechnology Ltd) covering wearable automatic injection devices for subcutaneous delivery. The core antibody composition-of-matter patent AU2013257402A1 (AbbVie Biotechnology Ltd) is inactive, consistent with biosimilar market entry from 2016 onward. The remaining 18 patents are inactive or in PCT expired status.
Data and insights on this page are based on a limited patent, clinical, and biopharma intelligence dataset and are for reference only. Figures may not represent the complete drug development landscape.